Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo Nordisk (NVO) said on Wednesday that its emissions rose by nearly a quarter in 2024 and will continue to increase up to ...

Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...

Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...

Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...